Regenxbio Inc (RGNX)
Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
News
Regenxbio Inc Sees Remarkable Rise in Earnings and Revenue During Q3 2023
Regenxbio Inc Reports Deficit in Q1 2023 Amid Sluggish Sales Performance
Failed to break-even despite of surge in Revenues, in the fiscal span closing June 30 2022
The Diminishing Returns have enlarged more at the amid the fiscal period ending September 30 2022
A deficit of $-0.67 per Share at RGNX over the financial third quarter of 2017